AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00655499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: 180 mg/kg
Study NCT00655499 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Chromogenic in situ hybridization
Study NCT00655499 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization
Study NCT00655499 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Study NCT04607941 — intervention group
Intervention type: OTHER
Intervention: Phone interviews
Description: A small amount of subjects will be selected at random for phone interviews.
Study NCT03809091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole genome sequencing
Description: Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
Study NCT04371640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 1 MG/ML
Description: Oral solution
Study NCT04371640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study NCT00644904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT00644904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D3
Study NCT01946672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower-limb drainage isotopic intraoperative detection
Description: A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
Study NCT02456636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fee-for-Service Model (FFS, In clinic individual visits)
Description: To be performed by participant's doctor or other healthcare professional in their doctor's office.
Study NCT02456636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Centered Medical Home (PCMH, In clinic group visits)
Description: To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
Study NCT00655499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Study NCT03140670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUCAPARIB
Description: Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
Study NCT00028548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R(+)XK469
Study NCT03965949 — intervention group
Intervention type: DRUG
Intervention: Hormone Replacement cycle 1
Description: Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
Study NCT02456636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease Management (DM, Phone group visits)
Description: To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
Study NCT02281955 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
Study NCT02281955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or alternative)
Description: Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
Study NCT02281955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment for surgical evaluation
Description: Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
Study NCT02427568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDMA (125 mg)
Description: Two sessions of MDMA (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
Study NCT02427568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sessions of placebo (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
Study NCT02427568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy
Study NCT02427568 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy
Study NCT03965949 — intervention group
Intervention type: DRUG
Intervention: Hormone Replacement cycle 2
Description: Hormone Replacement cycle with GnRHa suppression
Study NCT00070486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: given IV
Study NCT04603781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBD Isolate
Description: 300 mg. daily dose of CBD Isolate Oil
Study NCT04603781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Full Spectrum CBD Oil
Description: 300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
Study NCT04603781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broad-Spectrum CBD Oil
Description: 300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
Study NCT04603781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: MCT Oil with mint flavoring
Study NCT02417116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tear supplement
Description: Application as required to improve comfort
Study NCT02417116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tear supplement 2
Description: Application as required to improve comfort
Study NCT02417116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 nutrition supplement
Description: Taken each day
Study NCT02417116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye bag
Description: Applied following microwave heating to closed eyelids for 5 minutes each day
Study NCT02417116 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Application as required to improve comfort
Study NCT00070486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: given PO
Study NCT00070486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: given IV
Study NCT00070486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton
Description: given PO
Study NCT01510015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: variable dose
Study NCT03122821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Transcranial direct stimulation+Mental Imagery
Description: The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks
Study NCT03122821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Direct Stimulation +Mental Imagery
Description: The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks
Study NCT05186103 — intervention group
Intervention type: OTHER
Intervention: observation
Description: The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
Study NCT00031655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSCT
Study NCT03351400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells administered to participants
Description: Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
Study NCT00031655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes
Description: Given IV
Study NCT00031655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO
Study NCT02867982 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subcrestal implant placement
Description: Dental implants placed 2 mm below the alveolar ridge
Study NCT02867982 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paracrestal implant placement
Description: Dental implants placed flush to the alveolar ridge
Study NCT02867982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: prophylactic antibiotics
Description: amoxicillin was used before and after implant surgery for prophylactic reasons
Study NCT02867982 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: dental implant
Description: dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
Study NCT00031655 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00031655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00031655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00031655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00031655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSCT
Study NCT02867982 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: x-ray examination
Description: radiographies were taken before treatment and at different time point during the follow-up period
Study NCT01215617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Interval training
Description: Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
Study NCT01215617 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Standard medical treatment
Study NCT00635739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: powdered, 46g supplement dissolved in fluids, twice daily
Study NCT01259570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Skimmilk enriched with VD encapsulated in CM
Study NCT01259570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: VD will be dissolved in milkfat and homogenized into skimmilk
Study NCT01259570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: group 3
Description: 3% fat milk wherein the VD will be in CM
Study NCT01259570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 4
Description: Placebo: un-enriched skimmilk.
Study NCT02704052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Real time enoxaparin dose adjustment
Description: Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
Study NCT02704052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard enoxaparin dose
Description: Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
Study NCT03002194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutometer
Description: Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
Study NCT03002194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photographs
Description: Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
Study NCT03450642 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
Study NCT04559698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-affirmative CBT training
Description: Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
Study NCT01278030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D echo-guided LV lead placement
Description: Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
Study NCT04284878 — intervention group
Intervention type: GENETIC
Intervention: PCR-RFLP
Description: PCR-Restriction fragment length polymorphism
Study NCT00635739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo
Description: powdered, 46g supplement dissolved in fluids, twice daily
Study NCT04610892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6570
Description: MEDI6570
Study NCT04610892 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer
Study NCT04627181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
Study NCT04627181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycobalamin
Description: Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
Study NCT04627181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
Study NCT04627181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
Study NCT04627181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
Study NCT04627181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
Study NCT03989973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastroscopy
Description: Gastroscopy
Study NCT02146703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, and S-1
Description: Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14
Study NCT00445939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 160 mg at Week 0, 80 mg at Week 2
Study NCT00445939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 80 mg at Week 0, 40 mg at Week 2
Study NCT00445939 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo at Week 0 and Week 2
Study NCT02415751 — intervention group
Intervention type: BEHAVIORAL
Intervention: heart failure self-care education
Description: It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
Study NCT01524965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate mobilisation after locking-plate osteosynthesis
Description: Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management.
Study NCT01524965 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard mobilisation after locking plate osteosynthesis
Description: Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management.
Study NCT01524965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis with a locking plate (Philos)
Description: Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
Study NCT01524965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis with a locking plate (Philos)
Description: Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
Study NCT04609358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group
Description: When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.